Long-Acting GLP-1 RAs Exenatide (Bydureon) In 1987, scientists discovered that GLP-1 promotes insulin secretion, and five years later, an entero-insulin analogue, Exendin-4, which is 53% homologous to GLP-1, was isolated from the saliva of the Mexican giant lizard, later known as exenatide, which has GLP-1 receptor agonist activity and a half-life of 2.4 hours
It activates two receptors GLP-1 and GIP
Food cravings appeared to be significantly reduced by semaglutide, which may make it easier for people to stick to healthier eating habits and lose weight
Step 2: Choose a Legitimate Platform What a Legitimate Platform Has Licensed independent providers: prescribing done by MDs, DOs, or NPs not the company itself Named pharmacy partner: you can ask which compounding pharmacy they use and get a clear answer Certificate of Analysis available: independent batch testing documentation provided on request HIPAA-compliant infrastructure: dual-database PHI isolation, signed BAAs with all vendors Ongoing monitoring: mandatory monthly provider re-reviews, not just a one-time prescription Full refund if declined: automatic refund if the provider does not approve your intake RED FLAGS AVOID THESE PLATFORMS Be very cautious of platforms that: Cannot name their pharmacy or provide a Certificate of Analysis Claim to offer oral semaglutide compounds Price everything under $100/month all-in without explanation Do not require a licensed provider prescription and consultation Have no ongoing clinical monitoring after the initial prescription Use high-pressure sales tactics to push you toward a specific medication before assessment Step 3: Complete the Medical Intake (10 Minutes) The clinical intake form is the core of your asynchronous consultation
The Therapeutic Impact on Diabetes and Obesity GLP-1 agonists exert a profound impact on the treatment of diabetes and obesity, providing numerous advantages that include: Promoting considerable weight loss Contributing to diminished appetite overall Offering potential for sustained weight management (as evidenced by 72-week studies on weight loss outcomes) Reducing caloric intake through suppressed hunger, which fosters better eating habits Consequently, GLP-1 agonists stand as an important asset in endeavors towards losing and maintaining healthy body weight
Identifying this brain area should help scientists find GLP-1 drugs that target the reward system while avoiding areas involved in appetite, Gler says
